82 related articles for article (PubMed ID: 9731208)
1. An allosteric drug, o,o'-bismyristoyl thiamine disulfide, suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 Tat and NF-kappa B.
Shoji S; Furuishi K; Ogata A; Yamataka K; Tachibana K; Mukai R; Uda A; Harano K; Matsushita S; Misumi S
Biochem Biophys Res Commun; 1998 Aug; 249(3):745-53. PubMed ID: 9731208
[TBL] [Abstract][Full Text] [Related]
2. Thiamine disulfide as a potent inhibitor of human immunodeficiency virus (type-1) production.
Shoji S; Furuishi K; Misumi S; Miyazaki T; Kino M; Yamataka K
Biochem Biophys Res Commun; 1994 Nov; 205(1):967-75. PubMed ID: 7999140
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication.
McAllister JJ; Phillips D; Millhouse S; Conner J; Hogan T; Ross HL; Wigdahl B
Virology; 2000 Sep; 274(2):262-77. PubMed ID: 10964770
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human immunodeficiency virus type 1 replication by blocking IkappaB kinase with noraristeromycin.
Asamitsu K; Yamaguchi T; Nakata K; Hibi Y; Victoriano AF; Imai K; Onozaki K; Kitade Y; Okamoto T
J Biochem; 2008 Nov; 144(5):581-9. PubMed ID: 18713798
[TBL] [Abstract][Full Text] [Related]
5. A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor.
Montembault M; Vo-Thanh G; Deyine A; Fargeas V; Villiéras M; Adjou A; Dubreuil D; Esquieu D; Grégoire C; Opi S; Péloponèse JM; Campbell G; Watkins J; de Mareuil J; Aubertin AM; Bailly C; Loret E; Lebreton J
Bioorg Med Chem Lett; 2004 Mar; 14(6):1543-6. PubMed ID: 15006399
[TBL] [Abstract][Full Text] [Related]
6. Functional cross-talk of HIV-1 Tat with p53 through its C-terminal domain.
Ariumi Y; Kaida A; Hatanaka M; Shimotohno K
Biochem Biophys Res Commun; 2001 Sep; 287(2):556-61. PubMed ID: 11554765
[TBL] [Abstract][Full Text] [Related]
7. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication.
Su J; Naghavi MH; Jejcic A; Horal P; Furuta Y; Wu YP; Li SL; Hall WW; Goobar-Larsson L; Svennerholm B; Vahlne A
J Hum Virol; 2001; 4(1):8-15. PubMed ID: 11213934
[TBL] [Abstract][Full Text] [Related]
8. Recent status of HIV-1 gene expression inhibitors.
Baba M
Antiviral Res; 2006 Sep; 71(2-3):301-6. PubMed ID: 16488488
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional control of HIV replication by multiple modulators and their implication for a novel antiviral therapy.
Victoriano AF; Okamoto T
AIDS Res Hum Retroviruses; 2012 Feb; 28(2):125-38. PubMed ID: 22077140
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
11. The HIV-1 Tat transactivator protein: a therapeutic target?
Fulcher AJ; Jans DA
IUBMB Life; 2003 Dec; 55(12):669-80. PubMed ID: 14769003
[TBL] [Abstract][Full Text] [Related]
12. 4-Phenylcoumarins as HIV transcription inhibitors.
Bedoya LM; Beltrán M; Sancho R; Olmedo DA; Sánchez-Palomino S; del Olmo E; López-Pérez JL; Muñoz E; San Feliciano A; Alcamí J
Bioorg Med Chem Lett; 2005 Oct; 15(20):4447-50. PubMed ID: 16137881
[TBL] [Abstract][Full Text] [Related]
13. A 1,8-naphthyridone derivative targets the HIV-1 Tat-mediated transcription and potently inhibits the HIV-1 replication.
Massari S; Daelemans D; Barreca ML; Knezevich A; Sabatini S; Cecchetti V; Marcello A; Pannecouque C; Tabarrini O
J Med Chem; 2010 Jan; 53(2):641-8. PubMed ID: 19958026
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of protein-RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules.
Mei HY; Cui M; Heldsinger A; Lemrow SM; Loo JA; Sannes-Lowery KA; Sharmeen L; Czarnik AW
Biochemistry; 1998 Oct; 37(40):14204-12. PubMed ID: 9760258
[TBL] [Abstract][Full Text] [Related]
15. Reciprocal modulation of transcriptional activities between HIV-1 Tat and MHC class II transactivator CIITA.
Okamoto H; Asamitsu K; Nishimura H; Kamatani N; Okamoto T
Biochem Biophys Res Commun; 2000 Dec; 279(2):494-9. PubMed ID: 11118314
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37.
Okamoto H; Cujec TP; Okamoto M; Peterlin BM; Baba M; Okamoto T
Virology; 2000 Jul; 272(2):402-8. PubMed ID: 10873784
[TBL] [Abstract][Full Text] [Related]
17. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.
Maggiorella MT; Baroncelli S; Michelini Z; Fanales-Belasio E; Moretti S; Sernicola L; Cara A; Negri DR; Buttò S; Fiorelli V; Tripiciano A; Scoglio A; Caputo A; Borsetti A; Ridolfi B; Bona R; ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Ciccozzi M; Heeney J; Titti F; Cafaro A; Ensoli B
Vaccine; 2004 Sep; 22(25-26):3258-69. PubMed ID: 15308348
[TBL] [Abstract][Full Text] [Related]
18. Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1.
Shapiro L; Pott GB; Ralston AH
FASEB J; 2001 Jan; 15(1):115-122. PubMed ID: 11149899
[TBL] [Abstract][Full Text] [Related]
19. Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR).
Schafer EA; Venkatachari NJ; Ayyavoo V
Antiviral Res; 2006 Dec; 72(3):224-32. PubMed ID: 16889838
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
